In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Resolve and Takeda work together to develop nuclease proteins for lupus

Executive Summary

Resolve Therapeutics LLC (targeted biologics for lupus) has found its first major pharma partner through a new deal with Takeda Pharmaceutical Co. Ltd. The companies will further develop Resolve’s preclinical lupus candidate RSLV132, with Takeda retaining an exclusive option for global rights to the agent and all other compounds in the start-up’s pipeline.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies